LifeSci Advisors Initiates Coverage of Ignyta

Here is some information on Ignyta and it’s ALK inhibitor, RXDX-101, which was recently licensed from Nerviano.

http://lifesciadvisors.com/news/lifesci-advisors-initiates-coverage-of-ignyta-inc/

http://lifesciadvisors.com/news/preliminary-data-from-ignytas-phase-iii-trial-presented-at-lung-cancer-meeting/

This entry was posted in Lung cancer, NMS-E628, Research. Bookmark the permalink.

Leave a Reply